October 31, 2024
Argenica Therapeutics (ASX:AGN) strategic leap in neonatal brain protection gains FDA’s support
With FDA Orphan Drug and Rare Pediatric Disease designations, Argenica Therapeutics (ASX:AGN) strengthens its path forward for ARG-006, a promising treatment for neonatal brain injuries in hypoxic-ischaemic encephalopathy (HIE).